In the past week, ALT stock has gone down by -1.03%, with a monthly decline of -23.59% and a quarterly plunge of -6.69%. The volatility ratio for the week is 7.42%, and the volatility levels for the last 30 days are 10.15% for Altimmune Inc The simple moving average for the last 20 days is -17.93% for ALT’s stock, with a simple moving average of 57.45% for the last 200 days.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
ALT has 36-month beta value of 0.04. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALT is 53.18M, and currently, short sellers hold a 20.33% ratio of that float. The average trading volume of ALT on March 27, 2024 was 6.49M shares.
ALT) stock’s latest price update
Altimmune Inc (NASDAQ: ALT)’s stock price has gone rise by 1.41 in comparison to its previous close of 8.53, however, the company has experienced a -1.03% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-20 that GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.
Analysts’ Opinion of ALT
Many brokerage firms have already submitted their reports for ALT stocks, with Goldman repeating the rating for ALT by listing it as a “Neutral.” The predicted price for ALT in the upcoming period, according to Goldman is $13 based on the research report published on January 24, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ALT reach a price target of $6, previously predicting the price at $20. The rating they have provided for ALT stocks is “Neutral” according to the report published on March 22nd, 2023.
Goldman gave a rating of “Buy” to ALT, setting the target price at $20 in the report published on December 01st of the previous year.
ALT Trading at -14.10% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.71% of loss for the given period.
Volatility was left at 10.15%, however, over the last 30 days, the volatility rate increased by 7.42%, as shares sank -37.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.92% lower at present.
During the last 5 trading sessions, ALT fell by -1.03%, which changed the moving average for the period of 200-days by +111.49% in comparison to the 20-day moving average, which settled at $10.28. In addition, Altimmune Inc saw -23.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Drutz David, who purchase 300 shares at the price of $2.88 back on Aug 15 ’23. After this action, Drutz David now owns 29,785 shares of Altimmune Inc, valued at $862 using the latest closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -306.09 for the present operating margin
- -111.53 for the gross margin
The net margin for Altimmune Inc stands at -270.07. The total capital return value is set at -0.55. Equity return is now at value -44.15, with -40.05 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -97.19. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 410.58.
Currently, EBITDA for the company is -84.9 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 1357.3. The receivables turnover for the company is 0.06for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.89.
Conclusion
To put it simply, Altimmune Inc (ALT) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
